Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022

/PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced...

Related Keywords

Italy ,Ankara ,Turkey ,United States ,Rome ,Lazio ,Switzerland ,American ,Eleanor Perkin ,Prnewswire Nouscom ,Rick Davis ,Marwang Fakih ,Sylvie Berrebi ,Elisa Scarselli ,American Association For Cancer Research ,Linkedin ,Society For Immunotherapy Of Cancer ,Late Breaking ,Cancer Research ,Microsatellite Instable High ,Annual Meeting ,Medical Oncology Specialist ,Duarte California ,Chief Scientific Officer ,Presentation Details ,Microsatellite Instability ,Great Ape Adenoviral ,Modified Vaccinia Ankara ,Nouscom ,